$APRE
Aprea Therapeutics, Inc.

2023 Q3 Form 10-Q Financial Statement

#000155837023014405 Filed on August 10, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q2
Revenue $320.0K $249.7K $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.720M $1.699M $15.63M
YoY Change -44.2% -89.13% 367.61%
% of Gross Profit
Research & Development $2.123M $2.203M $6.812M
YoY Change 89.93% -67.66% 2.36%
% of Gross Profit
Depreciation & Amortization $0.00 $220.00 $3.730K
YoY Change -100.0% -94.1% -44.49%
% of Gross Profit
Operating Expenses $3.842M $3.901M $98.47M
YoY Change -8.52% -96.04% 884.89%
Operating Profit -$3.523M -$3.652M -$98.47M
YoY Change -16.13% -96.29%
Interest Expense $321.2K $336.2K $52.49K
YoY Change 112.55% 540.53% -9027.04%
% of Operating Profit
Other Income/Expense, Net $318.3K $392.6K $207.1K
YoY Change 81.41% 89.6% -181.7%
Pretax Income -$3.200M -$3.259M -$98.26M
YoY Change -20.49% -96.68% 858.52%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$3.205M -$3.259M -$98.26M
YoY Change -20.38% -96.68% 858.52%
Net Earnings / Revenue -1001.41% -1305.26%
Basic Earnings Per Share -$0.86 -$0.87 -$4.34
Diluted Earnings Per Share -$0.85 -$0.87 -$4.34
COMMON SHARES
Basic Shares Outstanding 3.737M 3.732M 22.66M
Diluted Shares Outstanding 3.732M 3.732M 22.66M

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $25.40M $27.69M $39.06M
YoY Change -23.29% -29.13% -44.04%
Cash & Equivalents $25.40M $27.69M $39.06M
Short-Term Investments
Other Short-Term Assets $300.0K $953.7K $1.401M
YoY Change -16.94% -31.92% -6.26%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $25.64M $28.64M $40.46M
YoY Change -23.4% -29.22% -43.25%
LONG-TERM ASSETS
Property, Plant & Equipment $86.20K $1.687K $20.26K
YoY Change 604.4% -91.67% -34.56%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $40.18K $29.36K
YoY Change -100.0% 36.86% -0.07%
Total Long-Term Assets $126.6K $41.87K $220.6K
YoY Change -14.5% -81.02% -12.27%
TOTAL ASSETS
Total Short-Term Assets $25.64M $28.64M $40.46M
Total Long-Term Assets $126.6K $41.87K $220.6K
Total Assets $25.77M $28.68M $40.68M
YoY Change -23.36% -29.5% -43.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $862.6K $1.131M $3.990M
YoY Change -24.08% -71.65% 68.96%
Accrued Expenses $3.300M $2.820M $3.694M
YoY Change 15.3% -23.68% -55.15%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.166M $3.951M $7.684M
YoY Change 4.2% -48.59% -27.49%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $4.166M $3.951M $7.684M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $4.200M $3.951M $7.684M
YoY Change 5.05% -48.59% -27.49%
SHAREHOLDERS EQUITY
Retained Earnings -$304.6M -$301.4M -$287.3M
YoY Change 4.56% 4.91% 75.28%
Common Stock $3.736K $3.731K $23.40K
YoY Change -92.85% -84.06% 10.45%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $20.29M $23.42M -$35.78M
YoY Change
Total Liabilities & Shareholders Equity $25.77M $28.68M $40.68M
YoY Change -23.36% -29.5% -43.14%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q2
OPERATING ACTIVITIES
Net Income -$3.205M -$3.259M -$98.26M
YoY Change -20.38% -96.68% 858.52%
Depreciation, Depletion And Amortization $0.00 $220.00 $3.730K
YoY Change -100.0% -94.1% -44.49%
Cash From Operating Activities -$2.240M -$3.217M -$8.903M
YoY Change -66.02% -63.87% 14.81%
INVESTING ACTIVITIES
Capital Expenditures $90.00K $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$90.00K $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -2.240M -3.217M -8.903M
Cash From Investing Activities -90.00K 0.000
Cash From Financing Activities 0.000 0.000 0.000
Net Change In Cash -2.330M -3.217M -8.903M
YoY Change -61.22% -63.87% 14.81%
FREE CASH FLOW
Cash From Operating Activities -$2.240M -$3.217M -$8.903M
Capital Expenditures $90.00K $0.00
Free Cash Flow -$2.330M -$8.903M
YoY Change -64.66% 14.81%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.87
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-86.72
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.18
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-95.31
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3731571
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1133092
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3497329
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1114189
dei Entity Central Index Key
EntityCentralIndexKey
0001781983
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3731571
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2655269
CY2023Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.05
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39069
dei Entity Registrant Name
EntityRegistrantName
Aprea Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-2246769
dei Entity Address Address Line1
EntityAddressAddressLine1
3805 Old Easton Road
dei Entity Address City Or Town
EntityAddressCityOrTown
Doylestown
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
18902
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
463-9385
dei Security12b Title
Security12bTitle
Common stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
APRE
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
3736673
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27685131
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28786647
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
953670
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1366859
CY2023Q2 us-gaap Assets Current
AssetsCurrent
28638801
CY2022Q4 us-gaap Assets Current
AssetsCurrent
30153506
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1687
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2321
CY2023Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
40180
CY2023Q2 us-gaap Assets
Assets
28680668
CY2022Q4 us-gaap Assets
Assets
30155827
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1131197
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
842754
CY2023Q2 apre Accrued Liabilities And Employee Related Liabilities Current
AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
2819624
CY2022Q4 apre Accrued Liabilities And Employee Related Liabilities Current
AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
2358332
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3950821
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3201086
CY2023Q2 us-gaap Liabilities
Liabilities
3950821
CY2022Q4 us-gaap Liabilities
Liabilities
3201086
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3731571
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2655269
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
3731
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
2655
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
335485317
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
330060836
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-10634872
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-10623408
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-301435392
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-293796405
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
23418784
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
25643678
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
28680668
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
30155827
CY2023Q2 us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
249688
us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
249688
CY2023Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
2202657
CY2022Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
6811609
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
3459199
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
10901186
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1698712
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15633738
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5064673
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19619036
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
14801615
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
157655
CY2022Q2 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
76020184
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
76020184
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
3901369
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
98465531
us-gaap Operating Expenses
OperatingExpenses
8523872
us-gaap Operating Expenses
OperatingExpenses
106540406
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3651681
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-98465531
us-gaap Operating Income Loss
OperatingIncomeLoss
-8274184
us-gaap Operating Income Loss
OperatingIncomeLoss
-106540406
CY2023Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
336221
CY2022Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
52491
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
592631
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
54462
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
56363
CY2022Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
154566
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
42566
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
290777
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
392584
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
207057
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
635197
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
345239
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-3259097
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-98258474
us-gaap Net Income Loss
NetIncomeLoss
-7638987
us-gaap Net Income Loss
NetIncomeLoss
-106195167
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-73420
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
157655
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-11464
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
92150
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3332517
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-98100819
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7650451
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-106103017
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.87
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-86.72
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.18
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-95.31
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3731571
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1133092
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3497329
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1114189
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
49506964
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2084060
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-65505
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-7936693
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
43588826
CY2022Q2 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
1329699
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2602850
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27700000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-98258474
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-35777829
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
25643678
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4871865
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
16244
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
61956
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-4379890
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
26481978
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
269323
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-73420
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-3259097
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
23418784
us-gaap Profit Loss
ProfitLoss
-7638987
us-gaap Profit Loss
ProfitLoss
-106195167
apre Research And Development In Process Noncash
ResearchAndDevelopmentInProcessNoncash
72523293
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
634
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
6666
us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
285567
us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
16885675
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
120795
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
42566
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
290777
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-410246
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2126847
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
289605
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2288527
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
499516
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1756495
apre Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-107306
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6195985
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14397942
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5788918
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
648928
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5139990
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-1055995
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-14397942
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-5341
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
384305
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28786647
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53076052
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27725311
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
39062415
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27685131
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
39062415
CY2023Q2 us-gaap Restricted Cash
RestrictedCash
40180
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27725311
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
39062415
us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
123786
us-gaap Stock Issued1
StockIssued1
70107167
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Use of estimates</b>—The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses as of and during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates. Significant items subject to such estimates and assumptions, are used for, but not limited to, include stock-based compensation and accounting for research and development costs.</p>
CY2023Q2 us-gaap Restricted Cash
RestrictedCash
40000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
612225
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
595248
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
19997
CY2022Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
84900
us-gaap Operating Lease Expense
OperatingLeaseExpense
39995
us-gaap Operating Lease Expense
OperatingLeaseExpense
159716
apre Lessee Operating Lease Annual Base Rent
LesseeOperatingLeaseAnnualBaseRent
101000
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
60679
us-gaap Operating Lease Cost
OperatingLeaseCost
120795
CY2022Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
64057
us-gaap Operating Lease Payments
OperatingLeasePayments
128113
us-gaap Operating Lease Payments Use
OperatingLeasePaymentsUse
123786
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
153742
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
75012
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1275530
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1397977
CY2023Q2 apre Research And Development Related Liabilities Current
ResearchAndDevelopmentRelatedLiabilitiesCurrent
1256695
CY2022Q4 apre Research And Development Related Liabilities Current
ResearchAndDevelopmentRelatedLiabilitiesCurrent
688858
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
133657
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
196485
CY2023Q2 apre Accrued Liabilities And Employee Related Liabilities Current
AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
2819624
CY2022Q4 apre Accrued Liabilities And Employee Related Liabilities Current
AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
2358332
CY2023Q2 apre Stock Shares Authorized
StockSharesAuthorized
440000000
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
40000000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
apre Common Stock Number Of Voting Rights Per Share
CommonStockNumberOfVotingRightsPerShare
1
CY2020Q4 apre Universal Shelf Registration Maximum Amount To Be Issued
UniversalShelfRegistrationMaximumAmountToBeIssued
350000000.0
CY2020Q4 apre At Market Offering Program Maximum Amount To Be Issued
AtMarketOfferingProgramMaximumAmountToBeIssued
14744728
CY2020Q4 apre At Market Offering Commission Payable As Percentage Of Gross Proceeds From Sale Of Common Stock
AtMarketOfferingCommissionPayableAsPercentageOfGrossProceedsFromSaleOfCommonStock
0.03
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
269323
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14800000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
285567
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16900000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q2 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
100000
CY2022Q4 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
100000
us-gaap Loss Contingency Accrual Provision
LossContingencyAccrualProvision
0

Files In Submission

Name View Source Status
0001558370-23-014405-index-headers.html Edgar Link pending
0001558370-23-014405-index.html Edgar Link pending
0001558370-23-014405.txt Edgar Link pending
0001558370-23-014405-xbrl.zip Edgar Link pending
apre-20230630.xsd Edgar Link pending
apre-20230630x10q.htm Edgar Link pending
apre-20230630xex31d1.htm Edgar Link pending
apre-20230630xex31d2.htm Edgar Link pending
apre-20230630xex32d1.htm Edgar Link pending
apre-20230630xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
apre-20230630_cal.xml Edgar Link unprocessable
apre-20230630_def.xml Edgar Link unprocessable
apre-20230630_lab.xml Edgar Link unprocessable
apre-20230630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
apre-20230630x10q_htm.xml Edgar Link completed
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending